These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15853628)

  • 1. Endothelin receptor antagonists: an overview of their synthesis and structure-activity relationship.
    Iqbal J; Sanghia R; Das SK
    Mini Rev Med Chem; 2005 Apr; 5(4):381-408. PubMed ID: 15853628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P
    Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.
    Cody WL; He JX; DePue PL; Waite LA; Leonard DM; Sefler AM; Kaltenbronn JS; Haleen SJ; Walker DM; Flynn MA
    J Med Chem; 1995 Jul; 38(15):2809-19. PubMed ID: 7636842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin and endothelin antagonists in hypertension.
    Schiffrin EL
    J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney.
    Wellings RP; Corder R; Warner TD; Cristol JP; Thiemermann C; Vane JR
    Br J Pharmacol; 1994 Feb; 111(2):515-20. PubMed ID: 8004396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.
    Warner TD; Allcock GH; Vane JR
    Br J Pharmacol; 1994 May; 112(1):207-13. PubMed ID: 8032643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic implications of endothelin antagonists for cardiovascular diseases].
    Abassi Z; Ramadan R; Schwartz H; Hoffman A
    Harefuah; 2004 Jan; 143(1):47-53, 84. PubMed ID: 14748289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF.
    Warner TD; Allcock GH; Corder R; Vane JR
    Br J Pharmacol; 1993 Oct; 110(2):777-82. PubMed ID: 8242251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus.
    Hay DW; Luttmann MA; Beck G; Ohlstein EH
    Br J Pharmacol; 1996 Jul; 118(5):1209-17. PubMed ID: 8818345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions of endothelins and sarafotoxin 6c in the rat isolated perfused lung.
    Lal H; Woodward B; Williams KI
    Br J Pharmacol; 1995 Jun; 115(4):653-9. PubMed ID: 7582486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity studies of endothelin leading to novel peptide ETA antagonists.
    Hunt JT; Lee VG; McMullen D; Liu EC; Bolgar M; Delaney CL; Festin SM; Floyd DM; Hedberg A; Natarajan S
    Bioorg Med Chem; 1993 Jul; 1(1):59-65. PubMed ID: 8081838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for assessing endothelin ETA-receptor antagonists in preclinical studies.
    Okada M; Siegl PK; Nishikibe M
    Methods Find Exp Clin Pharmacol; 2002; 24(6):361-70. PubMed ID: 12224443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
    Goto K; Miyauchi T
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):91-101. PubMed ID: 12616854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
    Schiffrin EL; Turgeon A; Deng LY
    Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of endothelin-1-receptor subtypes in rat portal vein.
    Filippelli A; Falciani M; Palla A; D'Amico M; Vacca C; Rossi F
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):113-18. PubMed ID: 8656643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin ET
    Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelin antagonists with no selectivity for either receptor subtype ETA or ETB.
    Kikuchi T; Kubo K; Ohtaki T; Suzuki N; Asami T; Shimamoto N; Wakimasu M; Fujino M
    J Med Chem; 1993 Dec; 36(25):4087-93. PubMed ID: 8258832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.
    Doherty AM; Cody WL; DePue PL; He JX; Waite LA; Leonard DM; Leitz NL; Dudley DT; Rapundalo ST; Hingorani GP
    J Med Chem; 1993 Sep; 36(18):2585-94. PubMed ID: 8410970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.
    Seo B; Oemar BS; Siebenmann R; von Segesser L; Lüscher TF
    Circulation; 1994 Mar; 89(3):1203-8. PubMed ID: 8124808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperresponsiveness to ET-1 after treatment with a mixture of ETA and ETB receptor antagonists in the rabbit in vivo and in vitro.
    D'Orléans-Juste P; Yano M; Maurice MC; Gratton JP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S369-72. PubMed ID: 8587417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.